[{"id":"75f4c28c-eb8b-4196-9b08-aa3ae1b3d58f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03927261","created_at":"2021-01-29T07:19:14.814Z","updated_at":"2024-07-02T16:35:44.881Z","phase":"Phase 1","brief_title":"PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS","source_id_and_acronym":"NCT03927261","lead_sponsor":"Precigen, Inc","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRGN-3006"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 05/20/2019","start_date":" 05/20/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-06-23"},{"id":"ef1aabf7-1fcb-4011-936a-14714f9c8075","acronym":"","url":"https://clinicaltrials.gov/study/NCT03826082","created_at":"2021-01-18T18:53:53.107Z","updated_at":"2025-02-26T13:01:03.027Z","phase":"Phase 1","brief_title":"PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory CD33-Positive AML or High Risk MDS","source_id_and_acronym":"NCT03826082","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRGN-3006"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 04/01/2035","study_completion_date":" 04/01/2035","last_update_posted":"2019-02-04"}]